BOONTON, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE http://www.unigene.com) reported that its first patent covering its Site-Directed Bone Growth (SDBG) technology has issued. The technology, jointly invented in collaboration with Dr. Agnès Vignery at the Yale School of Medicine, is designed to facilitate and accelerate bone growth at precisely targeted locations in the body using a simple surgical procedure that can be performed on an outpatient basis with minimal invasiveness. Animal studies have shown that, in combination with one or more therapeutic compounds, SDBG can grow significant amounts of high quality bone.
